The utility of vedolizumab (VDZ) trough levels (VTL) in the management of patients with inflammatory bowel disease (IBD) has not been well defined. The aims of this study are to determine: the median VTL and frequency of antibodies, the correlation of VTL with C-reactive protein (CRP) and mucosal healing (MH), and change in clinical management based on VTL.